Clinical trials: Stage IV Lung Cancer AJCC v8
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer
This phase I trial studies the side effects and best dose of autologous dendritic cell-adenovirus CCL21 vaccine (CCL21-gene modified dendritic cell vaccine) combined with intravenous pembrolizumab, and to see how well they work…
- Conditions
- Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Trial name
- NCT03546361
- Testing
- Autologous Dendritic Cell-Adenovirus CCL21 Vaccine, Pembrolizumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
This phase I trial studies the safety, side effects and best dose of necitumumab when given together with osimertinib in treating patients with EGFR-mutant non-small cell lung cancer that is stage IV or has come back after a…
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT02496663
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 15 sites in United States
- Volunteers
- 138 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8
Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer
This phase Ib trial studies the best dose, safety, and effect of alisertib or sapanisertib, in combination with osimertinib, in treating patients with EGFR mutated stage IIIB or IV non-small cell lung cancer that does not respond…
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- NCT04479306
- Testing
- Alisertib, Osimertinib, Sapanisertib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8
Evaluating Modifiable Biomarkers for the Prediction of Immunotherapy Response and Toxicity
This study evaluates gut microbiome and functional status as modifiable biomarkers in predicting immunotherapy response and toxicity in patients with stage IV non-squamous non-small cell lung cancer receiving pembrolizumab alone…
- Conditions
- Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- NCT04954885
- Testing
- Biospecimen Collection, Physical Performance Testing, Questionnaire Administration
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
This phase II trial tests whether CXCR1/2 inhibitor SX-682 (SX-682) with pembrolizumab works to treat patients with stage IIIC or IV non-small cell lung cancer that has spread to other parts of the body (metastatic) or that has…
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT05570825
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Washington
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma
Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
This phase I trial tests the safety, side effects, and best dose of carfilzomib in combination with sotorasib in treating patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) that may have spread from where it first…
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT06249282
- Testing
- Biopsy, Biospecimen Collection, Carfilzomib
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
This phase I/II trial studies the best dose of selumetinib and how well it works with durvalumab and tremelimumab in treating participants with stage IV non-small cell lung cancer or that has come back.
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Trial name
- NCT03581487
- Testing
- Durvalumab, Selumetinib, Tremelimumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer
This phase II trial tests whether subcutaneous atezolizumab can be effectively given at home with medical care provided primarily using telemedicine in patients with non-small cell lung cancer.
- Conditions
- Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8
- Trial name
- NCT05340309
- Testing
- Atezolizumab and Recombinant Human Hyaluronidase, Survey Administration
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Southern California
Extensive-stage Small-cell Lung Cancer, Limited-stage Small-cell Lung Cancer
An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer
This phase I trial studies the side effects of 124I-hJAA-F11, and evaluates how well it works in diagnosing lung cancer. 124I-hJAA-F11 uses a known radioactive substance used in imaging called iodine 124 (124I).
- Conditions
- Extensive-stage Small-cell Lung Cancer, Limited-stage Small-cell Lung Cancer, Lung Non-Small Cell Carcinoma, Stage IIIA Lung Cancer
- Trial name
- NCT06427369
- Testing
- Radioconjugate, Positron Emission Tomography, Computed Tomography
- Sponsor
- Roswell Park Cancer Institute
Metastatic NSCLC
De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction
Immunotherapeutic approaches recently have demonstrated clinical efficacy in several cancer types, including melanoma and NSCLC.
- Trial name
- DIAL (NCT05255302)
- Testing
- Pembrolizumab before randomization, Chemotherapy, Pemetrexed
- Where
- 44 sites in France
- Volunteers
- 1,360 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change…
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT04181060
- Testing
- Bevacizumab, Biospecimen Collection, Computed Tomography
- Where
- 603 sites in United States
- Volunteers
- 300 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer
This phase I trial tests the safety, side effects, and best dose of osimertinib, cetuximab, and tucatinib in treating patients with EFGR-mutant non-small cell lung cancer that is stage IV or has come back (recurrent).
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT06067776
- Testing
- Cetuximab, Osimertinib, Tucatinib
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Jonathan Riess
Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
This phase Ib trial is to find out the best dose, possible benefits and/or side effects of osimertinib and tegavivint as first-line therapy in treating patients with EGFR-mutant non-small cell lung cancer that has spread to other…
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Trial name
- NCT04780568
- Testing
- Osimertinib, Tegavivint, Echocardiography Test
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma
Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial
This phase II trial tests whether a supportive care intervention (Resiliency among Older Adults Receiving Lung Cancer Treatment [ROAR-LCT]) is effective in improving physical and emotional wellbeing in patients with stage IIIA…
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Extensive Stage Lung Small Cell Carcinoma, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT05339022
- Testing
- Best Practice, Exercise Intervention, Physical Therapy
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
This National Cancer Institute (NCI)-NRG ALK Protocol phase II trial studies how well a combination of different biomarker/ALK inhibitors work in treating patients with stage IV ALK positive non-squamous non-small cell lung…
- Conditions
- Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Trial name
- NCT03737994
- Testing
- Alectinib, Brigatinib, Carboplatin
- Where
- 491 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Anorexia, Lung Non-Small Cell Carcinoma
Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer
This phase II/III trial studies how well anamorelin hydrochloride works in reducing anorexia in patients with non-small cell lung cancer that has spread to other places in the body.
- Conditions
- Anorexia, Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT03637816
- Testing
- Anamorelin Hydrochloride, Questionnaire Administration
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
This phase II trial tests how well CPI-613 (devimistat) in combination with hydroxychloroquine (HCQ) and 5-fluorouracil (5-FU) or gemcitabine works in patients with solid tumors that may have spread from where they first started…
- Conditions
- Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Adenocarcinoma
- Trial name
- NCT05733000
- Testing
- Biospecimen Collection, Computed Tomography, Devimistat
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Northwestern University
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back.
- Conditions
- Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma
- Trial name
- NCT03845296
- Testing
- Rucaparib
- Where
- 950 sites in United States
- Volunteers
- 64 people
- Sponsor
- SWOG Cancer Research Network
Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Neoplasm in the Lung
4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis
This trial studies how well 4 dimensional (D) positron emission tomography/computed tomography (PET/CT) works in diagnosing participants with lung or colorectal cancer that has spread to the liver and lung.
- Conditions
- Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Neoplasm in the Lung, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT00862680
- Testing
- 4-Dimensional Computed Tomography, 4D PET Scan
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
This phase II trial tests how well GT103 in combination with pembrolizumab works in treating patients with STK11 mutant non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or…
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT07017829
- Testing
- Anti-CFH Monoclonal Antibody GT103, Biopsy Procedure, Biospecimen Collection
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Roswell Park Cancer Institute